Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis

Completed

Conditions studied: GBS Positive, Women in Labor Given Vancomycin for Prophylaxis

In brief

While it is clear that intrapartum antibiotics reduce neonatal GBS infection rates, the mechanism by which these drugs prevent neonatal GBS is not well established. One postulated theory is antibiotics work to reduce bacterial load in the birth canal; thus decreasing fetal exposure during labor and delivery. To our knowledge, the relationship between vancomycin and vaginal GBS colony counts has never been studied. In this prospective cohort study, our objective is to determine the relationship between intrapartum IV vancomycin and vaginal GBS colony counts.

Key facts

Study ID

NCT02143154

Run by

Women and Infants Hospital of Rhode Island

People needed

77

Starts

2014-10-01

Expected to finish

2018-10-03

Last updated by the study team

2018-10-04

Who can join

Age: 18 and older, up to 48. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women with documented GBS-positive antenatal screening culture or documented GBS bacteruria during pregnancy with plan to receive vancomycin for intrapartum antibiotic prophylaxis,
• ability to give informed consent,
• aged 18-48,
• English and or Spanish speaking, admitted in labor or undergoing induction of labor

You may not qualify if…

• Inability to give consent,
• currently receiving antibiotics for another indication,
• recent antibiotic use (within the previous 7 days),
• allergy to vancomycin

Where it is running

• Women & Infants Hospital — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.